Compare the complementary effect of radiofrequency ablation technique besides chemotherapy in patients with metastatic liver tumors from breast and control group under chemotherapy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017010931062N2

Enrollment

Registered

2017-04-24

Start date

2017-02-19

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver metastases from breast cancer. Secondary malignant neoplasm of other specified sites

Interventions

Intervention 1: Case group will receive both RFA and chemotherapy Chemotherapy regimen FEC: Cycle length: 21 days - Duration of therapy: 6 to 8 cycles. Fluorouracil 500 mg/m2 IV - On

Treatment - Other

Case group will receive both RFA and chemotherapy Chemotherapy regimen FEC: Cycle length: 21 days - Duration of therapy: 6 to 8 cycles. Fluorouracil 500 mg/m2 IV - Once a day Epi

Control group will receive just chemotherapy Chemotherapy regimen FEC: Cycle length: 21 days - Duration of therapy: 6 to 8 cycles. Fluorouracil 500 mg/m2 IV - Once a day Epirubicin 100

Eligibility

Sex/Gender

Female

Age

35 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: liver metastatic lesion from breast tissue verified by pathology; liver metastatic lesion far from intrahepatic bile ducts; liver metastatic lesion far from great veins more than 3 cm Exclusion criteria: Acute febrile infection; Cr>2; Ascites; hepatic encephalopathy; INR>1.5; Bill>3; verified extrahepatic metastases; surgery candidates

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
?The status of residual liver tumour. Timepoint: 3 weeks after treatment, 3 months and 6 months after treatment. Method of measurement: Evaluate CT scan images with and without contrast.;Liver tomur size. Timepoint: 3 weeks after treatment, 3 months and 6 months after treatment. Method of measurement: Evaluate CT scan images with and without contrast.;Frequency of liver tumors. Timepoint: 3 weeks after treatment, 3 months and 6 months after treatment. Method of measurement: Evaluate CT scan images with and without contrast.;Contrast agent absorption by liver tumor. Timepoint: 3 weeks after treatment, 3 months and 6 months after treatment. Method of measurement: Evaluate CT scan images with and without contrast.	—

Measure

Time frame

?The status of residual liver tumour. Timepoint: 3 weeks after treatment, 3 months and 6 months after treatment. Method of measurement: Evaluate CT scan images with and without contrast.;Liver tomur size. Timepoint: 3 weeks after treatment, 3 months and 6 months after treatment. Method of measurement: Evaluate CT scan images with and without contrast.;Frequency of liver tumors. Timepoint: 3 weeks after treatment, 3 months and 6 months after treatment. Method of measurement: Evaluate CT scan images with and without contrast.;Contrast agent absorption by liver tumor. Timepoint: 3 weeks after treatment, 3 months and 6 months after treatment. Method of measurement: Evaluate CT scan images with and without contrast.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Mardanshahi

Mazandaran University of Medical Sciences

zmardanshahi@yahoo.com+98 911 156 5082

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026